Background and Objectives The efficacy of glucocorticoids (GCs) in treating systemic lupus erythematosus (SLE) is beyond doubt. However, GCs-related adverse effects (AEs) are multiple and serious. Despite the current available evidence suggesting to reduce daily doses of prednisone \7.5 mg/day, or even to withdraw it, in the real-life practice, it is not uncommon to see patients receiving medium doses (up to 30 mg/day prednisone or equivalent) or high doses (C30 mg/day). Methods We systematically reviewed the literature with a priori strategy, to assess the rate of AEs related to medium or high doses of GCs in patients with SLE, analyzing randomized control trials with at least one of the treatment groups including GCs alone at medium or high doses. Results We found a rate of 9/100 patients/year for hyperglycemias/diabetes, 25/100 patients/year for infections, and 12/100 patients/year for avascular necrosis of the hip. Interestingly, when adjusting for GC dose and treatment duration, we observed no difference in terms of AEs comparing patients receiving medium versus high doses. Conclusions In the era when treat-to-target strategies have been proposed in order to control SLE disease activity, improved health-related quality of life, and reduced morbidity and mortality, using GCs in a more restrictive way should be a goal to prevent major complications in patients with SLE.
Introduction
Glucocorticoids (GCs) are among the most potent immunosuppressive and anti-inflammatory drugs. Their efficacy in treating systemic lupus erythematosus (SLE) is beyond doubt. However, GCs-related side effects are multiple and serious. Indeed, in lupus patients, prednisone use has been consistently shown to increase irreversible damage, a major predictor of morbidity and mortality [1] . Despite the current available evidence suggesting to reduce daily doses of prednisone \7.5 mg/day, or even to withdraw it, sometimes physicians might struggle to achieve this goal [2] . Among others, Gladman et al. when reporting on the course of an inception SLE cohort, prospectively followed-up for at least 15 years, showed that overall 87.7% of patients received GCs, at a mean maximum dose of 37.7 mg/day [3] . Similarly, in real-life practice, it is not uncommon to see patients receiving medium doses (up to 30 mg/day) or high doses (C30 mg/day) [4] . Adverse effects (AEs) of GCs therapy, such as increased risk of infection, avascular osteonecrosis, osteoporosis, myopathy, diabetes mellitus or cushingoid features, as well as skin bruising and cataracts are known and have been well described, especially in studies conducted when GCs were among the few therapeutic tools for SLE management [1] . However, quantifying the risk of AEs related to medium or high doses of GCs is still challenging, especially in an era when patients are rarely receiving GCs alone.
Methods
When attempting to assess the rate of AEs related to medium or high doses of GCs in patients with SLE, using a pre-defined protocol, we systematically reviewed the literature selecting studies for evaluation when they met all of the following criteria: (i) Randomized control trials (RCTs), (ii) enrolled adult patients with SLE, (iii) at least one of the treatment groups includes corticosteroids alone at medium doses (up to 30 mg/day prednisone or equivalent) or high doses (C30 mg/day prednisone or equivalent), (iv) reporting rate of GC-related side effects (including hypertension, diabetes, reduction in bone mass index/ aseptic osteonecrosis). We searched the MEDLINE, EMBASE and CINAHL databases from their inception (starting in 1950) to December 2016. Medical subject headings (MeSH) terms used in the MEDLINE database search included 'systemic lupus erythematosus', 'corticosteroids', 'glucocorticoids'. Index terms were modified appropriately for the other databases. The Cochrane Library (the Cochrane Central Register of Controlled Trials and the Cochrane Database for Systematic Reviews) was also searched. This was supplemented by manually searching bibliographies of these articles and of previously published reviews.
Potential studies identified with the above search strategy were exported to an electronic reference management software program (RefWorks v.2.0). Duplicate studies were identified and removed using the filter functions ''exact duplicates'' and ''close duplicates.'' Quality assessments of the suitable RCTs and data extraction from them were done independently by two reviewers (E.M. and S.S.). In case of disagreement, consensus was aimed for and if it was not achieved, a third reviewer (M.J.C.) gave final judgment. It was pre-determined that the corresponding author of an included RCT would only be contacted if any data/information relevant to this meta-analysis was found missing in the published RCT. The research strategy is summarized in Fig. 1 .
We abstracted data for the AEs from every paper and entered them into a Microsoft Excel database. For the eight retained studies [5] [6] [7] [8] [9] [10] [11] [12] , the extracted data included study characteristics (setting, duration, design, treatment/intervention, patients characteristic, AE rate and details).
A steroid equivalence converter [13] was used to compare the different doses and type of steroids, according to treatment duration and relative drug potency. 
Results
Out of 102 screened studies, a total of 8 RTCs [5] [6] [7] [8] [9] [10] [11] [12] met the inclusion criteria, including 182 SLE patients receiving GCs alone at medium doses (up to 30 mg/day prednisone or equivalent) or high doses (C30 mg/day prednisone or equivalent). One should acknowledge that with the expanding therapeutic options for SLE treatment, over the years only a very limited number of RCTs with a ''glucocorticoid only'' arm were retrievable for our analysis. Study details, patients' characteristics and treatments protocols are shown in Table 1 . AEs for each study are described in Table 2 . When pooling together the adverse events reported in studies and adjusting for treatment duration, we found a rate of 9/100 patients/year for hyperglycemias/diabetes, 25/100 patients/year for infections, and 12/100 patients/year for avascular necrosis of the hip. Among the studies reporting the type of infection, respiratory tract and herpes zoster infections seemed to occur most frequently. However, most of the studies included in the analysis did not distinguish between mild from severe infections. When adjusting for GC dose (meant as prednisone equivalent, calculated according to Shimmer et al. [14] ) and treatment duration, we observed no difference in terms of AE rate comparing patients receiving medium versus high doses. This observation is in line with the ideas that GC-related AEs should be considered according to the level of activation of the genomic and non-genomic ways (low doses, up to 7.5 mg/day versus medium-high doses, C30 mg/day) [15] .
Discussion
Previous observation analyses reported that even low doses of GCs (e.g. as high as 6 mg/day) were associated with organ damage [2] . This aspect should be kept in mind when a steroid tapering scheme is planned, as it should aim to achieve doses of \30 mg/dL to really impact on the rate of GC-related AEs.
Even though RTC conditions do not entirely reflect everyday clinical practice and our analysis could only take into account the GC exposure during the RCT, it is of most importance that every effort should be made to avoid GC side effects. It should be remembered that medium-to-high GC doses are not the therapy of lupus, but part of the treatment of few severe lupus manifestations [15] . Concomitant use of immunosuppressive agents [16] , biological drugs [17, 18] and antimalarial drugs [19] may help keep daily doses of prednisone \7.5 mg/day, or even to withdraw it completely. In the era when treat-to-target strategies have been proposed in order to control disease activity, improve healthrelated quality of life, and reduce morbidity and mortality, using GCs in a more restrictive way should be a goal to prevent major complications in patients with SLE.
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